Mankind Pharma (MANKIND) offers a tactical buy-side technical rationale as Stochastic RSI flashes oversold reversal at 8.45 with STOCH(9,6) crossing up from 12.19 levels and Momentum(10) signaling buy at 28.60, indicating exhaustion selling near key pivot support amid pharma sector consolidation post recent correction. Price holding higher lows above 200-EMA (~₹2,299) with volume divergence confirming accumulation, while MACD histogram narrowing positively suggests imminent bullish crossover ahead of potential healthcare demand revival. Sustained break above ₹2,613 pivot targets ₹2,632-2,640 resistance (3-5% upside potential) aligning with neutral-to-bullish oscillator alignment.Warning-
Disclaimer– Registration granted by SEBI, membership of a SEBI recognized supervisory body (BSE) and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.
Disclosure– Investments in securities market are subject to market risks, read all the related documents carefully before investing.